Click HERE to view Webcast

Targeted Audience
This educational activity is specifically designed for hematologists, oncologists, internists and other physicians, physicians-in-training, and healthcare professionals (nurses and pharmacists) involved in and/or interested in lymphoma, myeloma, and related plasma cell disorders and their management.

Webcast Overview
This Webcast was taken directly from a satellite symposium held at the annual Lymphoma & Myeloma meeting on October 20, 2007 in New York City. The moderator, Ruben Niesvizky, MD, is joined by renowned experts in the field of hematology and hematologic malignancies. Novel management strategies for the treatment of multiple myeloma and non-Hodgkin lymphoma are highlighted with an emphasis on emerging agents and research initiatives.

Educational Objectives
After completing this activity, the participant will be able to:

1. Discuss the utilization of proteasome inhibitors and immunomodulators to optimally manage patients with multiple myeloma
2. Describe and distinguish novel therapeutic regimens which are clinically beneficial to patients with follicular non-Hodgkin lymphoma
3. Discuss novel therapeutic strategies and their incorporation in clinical practice for the treatment of patients with mantle cell lymphoma

Disclosure Statement
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex^®, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are encouraged to provide a balanced view of therapeutic options by utilizing generic names of several to ensure impartiality.

All faculty participating in an Imedex activity are required to disclose commitments to and/or relationships with pharmaceutical companies, biomedical device manufacturers or distributors, or others whose products or services may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.

All materials are included with the permission of the authors.

All Imedex staff members who are in a position to control the content of this activity have no financial relationships with any commercial interests that are relevant to this activity.

Faculty Listing and Disclosure Statements

Faculty
Ruben Niesvizky, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

David G. Maloney, MD, PhD
Fred Hutchinson Cancer Research Center
Seattle, Washington

John P. Leonard, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Faculty Disclosure
As an accredited provider of continuing medical education, Imedex, LLC is required to ask speakers to disclose any real or apparent conflict of interest they may have as related to the contents of their presentation(s). The existence of commercial or financial interests of speakers related to the subject matter of their presentation(s) should not be construed as implying bias or decreasing the value of their presentation(s). However, disclosure should help participants form their own judgments.

All speakers were independently selected by the organizing committee. Those speakers who disclosed affiliations or financial interests with the commercial organizations involved with products, to which they may refer, are listed below.

1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support

The following speakers have reported an affiliation with the supporter of this symposium:

Sponsorship Statement
This activity is sponsored by Imedex, LLC.

Accreditation Statement
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

In order to receive credit, participants must successfully complete the post-test and complete the online evaluation form. You will receive an online CME statement of credit to print for your records.

For questions regarding the accreditation of this activity, please contact
Imedex
4325 Alexander Drive
Alpharetta, GA 30022
Fax: +1(770) 751-7334
Email: enduring@imedex.com

Unapproved and Investigational Uses of Drug and Devices
This discussion may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.

The opinions expressed in this email case discussion are the opinions of the authors and do not necessarily reflect the opinions of Imedex, LLC or the American School of Oncology.

Support
The following company has provided an unrestricted educational grant in support of this activity: Millennium Pharmaceuticals, Inc.

Click HERE to view Webcast

System Requirements:

is required for proper viewing. Click here to download Pentium 500 processor or greater Windows 98/NT/2000/XP or Mac OS 9/X Microsoft Internet Explorer 5.5 or later (Firefox browser currently not supported) 128 MB of RAM Monitor settings: High color at 800 x 600 pixels Sound card and speakers Audio troubleshooting For general troubleshooting concerning audio or video playback issues consult the following Web link: http://support.microsoft.com/kb/306317.